CardioDx is touting new study data finding that its Corus CAD diagnostic is effective in helping physicians determining whether patients have obstructive coronary artery disease before recommending costlier tests and treatments.
In the study, the company's Corus CAD test was used on 98 geriatric patients, discovering that the diagnostic's risk scoring system fell well in line with physician's recommendations, as 91% of patients who scored low on the test were deemed not to need cardiological referrals.
CardioDx--a 2012 Fierce 15 company--said the results demonstrate Corus CAD's utility in primary care practices, possibly saving patients time and money by cutting down on unnecessary tests and procedures. The study is the latest in a string of data confirming the test's value, Chief Medical Officer Mark Monane said.
"As adoption increases, the Corus CAD test has the potential to yield greater healthcare efficiencies and reduced costs by decreasing noninvasive imaging and associated radiation and dye-induced side effects, as well as potentially reducing invasive coronary angiography in patients with a low likelihood of coronary artery blockages," Monane in a statement.
CardioDx secured Medicare coverage for the test back in August, making the test a covered benefit for more than 40 million enrollees in the U.S. Shortly afterward, the company snagged a $58 million investment round to fund its commercialization. CEO David Levison told FierceMedicalDevices that CardioDx will keep making its case to payers around the world to reimburse for the test, and the company is considering future applications for Corus CAD in arrhythmia and heart failure.
- read CardioDx's release
Special Report: CardioDx – 2012 Fierce 15